AGM 2022 Presentation

November 11, 2022November 11, 2022 Alterity Therapeutics

Post navigation

Appendix 4C – Q2 FY23 Quarterly Cash Flow Report
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics to Participate in the Sachs Associates 6^th Annual Neuroscience Innovation Forum

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

AGM 2022 Presentation

Related Posts

Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model

Prana receives $4.8 million R&D Tax Incentive Cash Refund

Prana Biotechnology 2014 Annual Report